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Background – The development of atopic dermatitis (AD) and other cutaneous hypersensitivities involves the
activation and differentiation of allergen-specific lymphocytes. Although hypersensitivity is often considered to
be a ‘T-helper 2-polarized’ lymphocyte response, recent evidence suggests that clinical disease is associated
with the development of multiple lymphocyte phenotypes.
Objectives – The purpose of this paper is to review recent advances in the understanding of the roles of lympho-
cytes, cytokines and noncytokine factors in the pathogenesis of canine AD.
Methods – Citation databases, abstracts and proceedings from international meetings published between 2001
and 2013 were reviewed in this update. Where necessary, older articles were included for background informa-
tion.
Results – The development of canine AD is associated with changes in both cutaneous and circulating lympho-
cyte populations. These lymphocyte responses are characterized by the production of a complex variety of cyto-
kines, including not only T-helper 2 but also T-helper 1, T-helper 17 and regulatory T-cell responses. In addition,
microarray gene expression analysis has enabled the identification of a number of noncytokine factors that
appear to be associated with atopic inflammation. These include the calcium-binding protein S100A8, serum
amyloid A and a number of protease inhibitors, as well as genes involved in epidermal barrier formation, innate
immunity receptors, cell cycle proteins and apoptosis.
Conclusions – The development of AD in dogs is characterized by the development of a delicate balance
between a variety of T-cell phenotypes and inflammatory mediators, including cytokines, chemokines and noncy-
tokine factors.
Introduction
The development of cutaneous hypersensitivity reactions
(including canine atopic dermatitis; AD) involves a com-
plex interaction between environmental antigens, genetic
predisposition and a number of disparate cell types. The
ultimate result of these interactions is the activation of
both T and B lymphocytes. The function of these lympho-
cytes is influenced in part by the nature of the inflamma-
tory cytokine and chemokine milieu in which they are
activated. Certain cytokines promote the development of
a ‘T-helper 2 (Th2)’ phenotype, which promotes the pro-
duction of immunoglobulin (Ig) E antibodies and favours
the production and recruitment of inflammatory cells typi-
cally associated with hypersensitivity, such as eosinoph-
ils. The development of new methods to evaluate gene
expression (such as gene expression microarrays)
has made it clear that canine AD is not completely a Th2
phenomenon. Instead, cutaneous hypersensitivity is the
result of a delicate balance between a variety of types of
T-cell responses and inflammatory mediators, including
not only Th2 cytokines, but also T-helper 1 (Th1),
T-helper 17 (Th17) and regulatory cytokines as well
as noncytokine factors. The purpose of this paper is
to review recent works investigating the roles of
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lymphocytes, cytokines, chemokines and the Th1–Th2
balance in canine AD.
Lymphocytes and cytokines in canine
atopic dermatitis
Historical perspective
At the time of the initial 2001 report of the ACVD Task
Force on Canine Atopic Dermatitis, much work had
already been performed to characterize the immune
response in humans with AD, as well as in mouse models
of the disease.1,2 This work had demonstrated a predomi-
nantly lymphocyte-driven inflammatory response charac-
terized by the expression of variable proportions of ‘Th2’
cytokines [e.g. interleukin (IL)-4, IL-5, IL-6, IL-9, IL-10 and
IL-13] and ‘Th1’ cytokines (e.g. IL-2 and interferon-c
(IFNc).1–6
At that time, however, there was still a very limited
amount of information regarding the cutaneous immune
response in canine AD. As had been found in humans,
CD3+ lymphocytes represented a major component of
the mononuclear inflammatory infiltrate in atopic dog
skin.7,8 Two studies demonstrated that both CD4+ and
CD8+ T lymphocytes could be found in increased num-
bers in lesional atopic dog skin.7,8 The dermal lympho-
cytes mostly exhibited T-cell receptors composed of the
ab chains, while epidermal lymphocytes could express
either ab or cd T-cell receptors.7
Even less information was available regarding the cyto-
kine production by T cells in dogs with AD. Analysis of
cutaneous mRNA transcripts demonstrated that IL-4 and
IL-5 were more commonly expressed in samples
obtained from the lesional skin of dogs with AD relative
to normal dogs.9 In contrast, gene expression of IL-2 and
IL-12 was more commonly found in normal dog skin, and
expression of IFNc did not differ significantly between
the two groups.9
Differences were also demonstrated in the function of
immune cells harvested from atopic dogs. Mitogen-pre-
treated peripheral blood mononuclear cells harvested
from atopic dogs were demonstrated to have a
decreased ability to suppress (and frequently enhanced)
mitogen- or histamine-stimulated cell proliferation of tar-
get cells.10 In contrast, untreated mononuclear cells had
an enhanced suppressor effect. The reasons for this
apparent paradox in activity were unclear. Possible rea-
sons for this effect included the presence of an enhanced
‘baseline’ proportion of suppressor cells in atopic
patients, leaving fewer cells remaining that were capable
of being further induced towards a suppressive pheno-
type.10
Finally, atopic dogs were relatively refractory to experi-
mentally induced hypersensitivity to the contact allergen
dinitrochlorobenzene, although they demonstrated
greater dermal induration and cellular lymphocytic infiltra-
tion (relative to healthy dogs) following intradermal
injection of the mitogens concanavalin A and phytohae-
magglutinin.11 These findings suggested a derangement
in the cell-mediated immune response in these dogs, pos-
sibly in the function of Langerhans cells, which are
required for the mediation of contact hypersensitivity but
not for the response to intradermal mitogens.11 Together,
these functional studies demonstrated evidence of an
abnormal and possibly enhanced nonspecific immunologi-
cal reactivity in atopic dogs, although the exact nature of
this reactivity remained to be determined.
Update on lymphocytes and cytokines in canine
atopic dermatitis
Lymphocytes
Lymphocytes are present in low numbers in normal
canine skin. Both CD4+ and CD8+ lymphocytes have been
demonstrated in the canine epidermis and dermis. Typi-
cally, CD8 cells predominate in the epidermis, while CD4
cells predominate in the dermis.8 Greater numbers of
both cell types are present in lesional and nonlesional ato-
pic epidermis as well as in lesional dermis relative to
healthy skin.8 In contrast, nonlesional dermis exhibited an
increase in CD8 cells only.8
Like other inflammatory cells, lymphocytes can be
recruited to inflamed or allergen-challenged skin. Patch
testing of experimentally sensitized beagles was associ-
ated with epidermal recruitment of lymphocytes, includ-
ing cd T cells.12–14 Similar results were seen after
epicutaneous sensitization of na€ıve Maltese–beagle
crossbred dogs, where exposure to the mite allergens
resulted in lymphocyte recruitment.15 Subsequent expo-
sure of the sensitized dogs further increased lymphocyte
numbers, suggesting an active role for these cells in the
developing hypersensitivity reaction.15 Intradermal injec-
tion of anti-canine IgE antibodies induces antigen-inde-
pendent cross-linking of mast cell-bound surface IgE,
resulting in degranulation and elaboration of inflammatory
mediators. This antigen-independent mast cell degranula-
tion has been demonstrated to induce the recruitment of
ab T cells in a fashion similar to that seen after injection
of allergen in atopic dogs.16
One means by which T lymphocytes may be recruited
to atopic skin is via expression of the chemokine receptor
CCR4. CCR4 is the receptor for the T-cell chemotactic
factor TARC [thymus and activation regulated chemokine;
chemokine (C-C motif) ligand 17; CCL17]. TARC has been
demonstrated to be upregulated by keratinocytes in
lesional canine AD.17 Circulating CCR4+ T cells are pres-
ent in greater numbers in spontaneously allergic and
experimentally sensitized dogs than in healthy nonallergic
dogs.18 In one study, circulating CCR4+ T cells were vari-
ably increased following environmental allergen expo-
sure.19 Expression of CCR4 mRNA has also been
demonstrated in atopic canine skin, where it is probably
associated with skin-homing T cells.20
There are also changes in circulating T-cell numbers in
dogs with AD. In one study, healthy dogs had a circulating
CD4+-to-CD8+ ratio of 1.7:1.21 In contrast, the atopic dogs
had a CD4+-to-CD8+ ratio of 2.1:1, while a subset of ato-
pic dogs without pyoderma had an even more exagger-
ated ratio of 2.97:1. In another study, dogs
epicutaneously sensitized by application of mite allergen
to tape-stripped skin had a greater percentage of CD4+
cells expressing the activation marker CD30 than dogs
that were not tape stripped during sensitization.22
Increased numbers of CD25+ CD4+ cells have also been
reported in experimentally sensitized and challenged
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dogs.19,22 Interpretation of these results can be compli-
cated by the dual nature of CD25, which may be
expressed on both activated and regulatory T cells
(Treg).23,24
Less is known about the behaviour of Treg in the path-
ogenesis of canine AD, partly because of difficulties
associated with conclusive identification of these cells.
Certain cell markers have been used as Treg markers,
but these may also be expressed by other cell types.
For example, CD25 represents the a-subunit of the IL-2
receptor present on the surface of thymus-derived Treg
cells.25 This molecule is also upregulated on activated
T cells, and thus the mere presence of CD25 expression
cannot be relied upon to identify a Treg phenotype.26
However, high levels of expression of CD25 (CD25high)
have been demonstrated to correlate with increased
expression of the regulatory transcript and protein
FOXP3 in dogs, and thus CD25high cells may be more
likely to correspond to Treg.24 Certain regulatory tran-
scripts (e.g. FOXP3) or cytokines [e.g. IL-10, transform-
ing growth factor-b (TGFb)] may be more reliably
associated with Treg cells. However, even this method
is not foolproof, because many of these factors also
have functions other than simple regulation (e.g. IL-10
may also mediate Th2-type inflammation). In addition, at
least six B- and T-regulatory phenotypes expressing dif-
ferent cell markers and transcripts have been identified
in humans and rodent models.27 Simultaneous evalua-
tion of multiple cell markers and/or cellular products may
therefore be required for unequivocal identification of
regulatory cells. Unfortunately, this is technically chal-
lenging and hampered by the lack of appropriate canine-
specific reagents. Nonetheless, some information can
be obtained from the evaluation of more limited data, as
will be discussed under ‘Regulatory cytokines’ else-
where in this article.
Cytokines, chemokines and other proteins in atopic
dermatitis
T-Helper 2 cytokines
T-Helper 2-type reactions promote the development of
humoral immunity and hypersensitivity responses.
Canine and human AD are no longer considered strictly
‘Th2-polarized’ immune responses, but evidence sug-
gests that Th2-type cytokines are involved in the develop-
ment and perpetuation of AD, particularly in the early
phases and in acute lesions.
Interleukin-4
Interleukin-4 is commonly considered the archetypical
Th2 cytokine. It is produced by some T cells, mast cells
and possibly basophils.28,29 Gene and protein expression
of IL-4 has been variably found in dogs with AD (Table 1).
In one study, IL-4 mRNA transcripts were found in the
skin of both healthy and atopic dogs, albeit more fre-
quently in atopic skin.9 Another study also found overex-
pression of IL-4 in atopic relative to healthy skin.30 In
contrast, others failed to detect IL-4 gene expression in
either atopic or healthy dog skin, or any significant differ-
ences in mRNA expression between lesional, nonlesional
or healthy skin.31,32
Similar inconsistencies can be found in data from
experimental models of AD. In one study, IL-4 expression
could not be detected at any time before or from 6 to
48 h after intradermal injection of anti-IgE in healthy dog
skin.33 Specific environmental challenge of Dermato-
phagoides spp.-sensitized beagles with mite extract has
not been associated with significant increases in IL-4
mRNA.12,34 Unfortunately, data from nonsensitized con-
trol dogs was not presented in the latter studies, preclud-
ing comparison to ‘normal’ dogs.
In another study, peripheral blood mononuclear cells
(PBMCs) harvested from dogs experimentally sensitized
to Japanese cedar (Cryptomeria japonica) showed con-
centration-dependent expression of IL-4 when cultured
with Japanese cedar pollen extract.35 In contrast, IL-4
mRNA expression was decreased in PBMCs harvested
from spontaneously allergic dogs compared with nonaller-
gic dogs.36 There were, furthermore, no significant
changes in IL-4 mRNA in PBMC harvested from dogs
after allergen-specific immunotherapy.36 However, a dif-
ferent study showed that immunotherapy using lipo-
some–nucleic acid immune complexes was associated
with both an improvement in clinical condition and a
decrease in PBMC IL-4 expression in atopic dogs.37
Finally, one study evaluating IL-4 protein expression using
enzyme-linked immunospot found that experimental sen-
sitization to mite allergens increased IL-4 protein produc-
tion by canine PBMCs.38
Thymic stromal lymphopoietin
Atopic canine skin exhibits increased transcription of thy-
mic stromal lymphopoietin (TSLP) compared with healthy
skin (Table 1).39 This cytokine is produced by keratino-
cytes and induces maturation and activation of dendritic
cells and mast cells.39 Dendritic cell activation in the pres-
ence of TSLP appears to foster a ‘Th2-promoting’ pheno-
type. Production of TSLP by primary canine keratinocytes
is induced by stimulation with ligands for Toll-like recep-
tor 3 (TLR3) and 4, but not TLR2 or TLR7.39
Interleukin-31
Interleukin-31 is a recently described cytokine thought to
play an important role in AD and pruritus. Although one
study failed to detect IL-31 mRNA expression in the skin
of dogs with AD (Table 1), subsequent work demon-
strated that stimulation of T cells from mite-sensitized
dogs with mite allergen and staphylococcal enterotoxin B
induced production of IL-31.38,40 The IL-31 a-subunit
receptor has been identified in canine dorsal root ganglia
as well as in the canine DH82 histiocytoma cell line,
where it was found to activate both the mitogen-activated
protein kinase and Janus kinase/signal transducers and
activators of transcription (JAK/STAT) signalling path-
ways.38,41 Interleukin-31 could be detected in >50% of
serum samples from atopic dogs, but not in dogs with
other inflammatory skin diseases or healthy dogs.41
Finally, administration of IL-31 induced pruritus in labora-
tory beagles.41
Other Th2-related cytokines
Other cytokines and chemokines commonly associated
with AD in dogs include IL-13, IL-5, MCP1 (monocyte
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Table 1. Cytokines, chemokines and lymphocyte numbers in spontaneous and experimental canine atopic dermatitis
Increased in skin Decreased in skin
Increased in
PBMCs, whole
blood or serum
Decreased in
PBMCs, whole
blood or serum
Not found or no
difference
Spontaneous disease
Cytokines and
their receptors
IL-1b,31 IL-2,30 IL-4,9,30 IL-5,9
IL-10,32 IL-12p40 (nonlesional skin
only),32 IL-12b2r,42 IL-13,32
IL-13a2r,42 IFNc,9,30–32 TNFa,30,31
TSLP39
TGFb30 IL-5,45 IL-3138,41 IL-4,36 IFNc36,37,45 IL-4,31,32 IL-6,30
IL-10,45,51
IL-12p35,30
IL-12p40,30
IL-31,40 TGFb32
Chemokines and
their receptors
CCL19,42 CCL28,42,52 CCR4,20
IP-10,42 MCP1,42 MCP2,42
MCP3,42
TARC17,31,42
CCL27 (lesional
relative to
nonlesional
skin)52
CCR418
Cell surface
receptors/
specific cell
types
CD4,8 CD88 CD421 CD4/FOXP351
Other immune
factors
S100A8,42,56,57 SAA/SAA3,56
SERPINB4,42,56,57 SPINK5,57
TIMP142,56
S100A855 FOXP332
Experimental models
Cytokines and
their receptors
IL-5,33 IL-6,12 IL-12p35,12 IL-13,12,33
IL-18,12 IFNc12
IL-4,35,38 IL-3138 IL-10,34 IFNc,35
TGFb34
IL-2,12 IL-4,12,33,34
IL-5,12 IL-6,33
IL-8,12 IL-10,12
IL-12p40,12
IL-13,34 IFNc,33
TNFa12
Chemokines and
their receptors
MCP1,33 RANTES,33 TARC12,33 CCR418,19 CCR419
RANTES12
Cell surface
receptors/
specific cell
types
CD4/CD2519,22
Cytokines: IL-1b, interleukin-1, a general pro-inflammatory cytokine that activates the acute-phase protein response and enhances recruitment of
inflammatory cells; IL-2, interleukin-2, a Th1 cytokine that stimulates T-lymphocyte proliferation; IL-4, interleukin-4, a Th2 cytokine that stimulates
IgE production; IL-5, interleukin-5, a Th2 cytokine that stimulates eosinophil proliferation and recruitment; IL-6, interleukin-6, a general pro-inflam-
matory cytokine that activates the acute-phase protein response and promotes lymphocyte growth; IL-10, interleukin-10, a regulatory T-cell cyto-
kine that has immunosuppressive effects on various inflammatory cells; IL-12, interleukin-12, a cytokine that induces the differentiation of na€ıve
T cells into Th2 cells; IL-12p35, the p35 subunit of IL-12; IL-12p40, the p40 subunit of IL-12; IL-12b2r, the signalling subunit of the IL-12 receptor
complex; IL-13, interleukin-13, a Th2 cytokine that stimulates IgE production; IL-13a2r, the high-affinity subunit of the IL-13 receptor complex;
IL-18, interleukin-18, a Th1 cytokine that induces production of interferon-c by T cells and natural killer cells; IL-31, interleukin-31, a Th2 cytokine
that promotes the sensation of pruritus; IFNc, interferon-c, a Th1 cytokine that activates macrophages and suppresses Th2 responses; TNFa,
tumour necrosis factor-a, a general pro-inflammatory cytokine that enhances recruitment of inflammatory cells; TSLP, thymic stromal lymphopoie-
tin, a Th2 cytokine that activates and enhances the release of Th2-promoting cytokines from dendritic cells; TGFb, transforming growth factor-b, a
regulatory T-cell cytokine that has immunosuppressive effects on various inflammatory cells.
Chemokines: CCL19, macrophage inhibitory protein 3b, a chemokine which is chemotactic for dendritic cells and lymphocytes; CCL28, a chemoki-
ne which is chemotactic for resting lymphocytes and eosinophils; CCL27, a chemokine which attracts skin-associated memory T cells; CCR4,
chemokine receptor 4, the receptor for the chemokines CCL17 (TARC) and CCL22 (MDC); MCP1, CCL2/macrophage chemotactic protein 1, a
chemokine which attracts mononuclear cells, basophils and eosinophils; MCP2, CCL8/macrophage chemotactic protein 2, a chemokine which
recruits IL-5-producing Th2 lymphocytes; MCP3, CCL7/macrophage chemotactic protein 3, a chemokine which attracts mononuclear cells,
basophils and eosinophils; RANTES: CCL5/regulated upon activation, normal T cell expressed and secreted, a chemokine that attracts monocytes,
T cells and eosinophils; TARC, CCL17/thymus- and activation-regulated chemokine, a chemokine that attracts T cells.
Cell types: CD4, T lymphocytes that interact with cells bearing major histocompatibility class II (MHC II) molecules and includes Th1, Th2 and
some suppressor lymphocytes; CD8, T lymphocytes that interact with cells bearing major histocompatibility class I (MHC I) molecules and
includes cytotoxic lymphocytes; CD4/FOXP3, a regulatory T cell that has immunosuppressive effects on various inflammatory cells; CD4/CD25
may refer to either a regulatory T cell or an activated T cell.
Other immune factors: FOXP3, Forkhead box P3, a regulatory protein that has immunosuppressive effects on various inflammatory cells; S100A8,
a pro-inflammatory protein that increases chemotaxis in neutrophils; SAA/SAA3, serum amyloid A3, one of several lipoproteins that are increased
during inflammation and are part of the acute-phase response; SERPINB4, serine peptidase inhibitor clade B, member 4/squamous cell carcinoma
antigen 2, an inhibitor of serine proteases; SPINK5, serine peptidase inhibitor Kazal type 5, an inhibitor of serine proteases that is involved in epi-
dermal and hair morphogenesis; TIMP1, tissue inhibitor of metalloproteinases type 1, an inhibitor of matrix metalloproteinases, which may play a
role in tissue fibrosis and remodelling.
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chemotactic protein 1; CCL2), RANTES (regulated upon
activation, normal T cell expressed and secreted; CCL5),
MCP3 (monocyte chemotactic protein 3; CCL7), TARC
and TSLP.9,17,32,39,42 Interleukin-10 has also been associ-
ated with allergic diseases; however, this cytokine may
mediate either Th2-type inflammation or act as a regula-
tory cytokine.32,43 Studies investigating the expression of
these mediators are summarized in Table 1.
T-Helper 1 cytokines
T-Helper 1 cytokines induce cell-mediated immune
responses and, to a certain extent, antagonize Th2
responses. Atopic diseases were originally considered to
involve a Th2–Th1 imbalance, but it is now known that
Th2 cytokine profiles predominate only during sensitiza-
tion and in acute lesions of AD. T-Helper 1 responses
contribute to the development of clinical disease, and
may predominate in chronic lesions.
Interferon-c
Interferon-c is considered the ‘canonical’ Th1 cytokine,
much as IL-4 is for Th2 immune responses.44 Interferon-c
mRNA transcripts have been detected in skin biopsies of
dogs with spontaneous AD, most frequently from chronic,
lichenified lesional skin.9 Levels in canine lesional atopic
skin are higher than in nonlesional or healthy skin.30–32
Intradermal injection of anti-IgE did not induce the tran-
scription of IFNc in the skin of healthy nonallergic bea-
gles, suggesting that it is not involved in immediate-
phase responses.33 In contrast, environmental allergen
challenge of mite-sensitized beagles induced increased
transcription of IFNc as well as IL-12p35 (although not IL-
12p40), primarily during the later stages of inflamma-
tion.12 Peripheral blood mononuclear cells from dogs with
spontaneous or experimentally induced AD have lower
levels of spontaneous and Dermatophagoides spp.-
induced IFNc expression than PBMCs from control dogs,
suggesting a Th2 PBMC phenotype.35,36,45 Expression of
IFNc in mite-sensitized dogs with AD increased after aller-
gen-specific immunotherapy, suggesting that immuno-
therapy was associated with induction of Th1 cells.36 In
contrast, a separate study evaluating the response to
allergen-specific immunotherapy failed to demonstrate
any increase in IFNc expression even in dogs with a good
clinical response.37
Interleukin-12
Interleukin-12 is composed of two subunits, IL-12p35 and
ILp40, which combine to form IL-12p70 (sometimes
referred to as IL-12p75).46,47 In humans, the IL-12p35
subunit can also be incorporated into the heterodimeric
cytokine IL-35, but this cytokine has not yet been identi-
fied in the dog.46 Messenger RNA for IL-12p35 appears
to be transcribed constitutively 48, but the protein is
secreted only in the heterodimer form.49 This discrepancy
complicates interpretation of gene transcription data for
this subunit, because mRNA expression does not neces-
sarily correlate with protein secretion. The IL-12p40 sub-
unit is not constitutively expressed or secreted and is
sometimes considered a more ‘specific’ indicator of Th1-
type inflammation.49 However, this subunit is also shared
by the heterodimeric cytokine IL-23.46 Interleukin-23 may
play a greater role in Th17 immune responses, which are
associated with mucosal immunity and may be involved
in autoimmune diseases.
Interleukin-12 expression is more varied in atopic dogs
than is IFNc expression (Table 1). In one study, neither
IL-12 subunit was differentially expressed in the skin of
atopic dogs, while another study found that nonlesional
atopic dog skin expressed more IL-12p40 than lesional
and healthy skin.30,32 A gene expression microarray study
found that canine lesional skin exhibited differential
expression of a number of Th1-associated inflammatory
factors, including the IL-12 receptor b2-subunit and
CXCL10 (interferon-c-inducible protein 10; IP-10), which
is chemotactic for monocytes and T cells.42
Ratios of Th1 to Th2
Some immunologists feel that it is more appropriate to
evaluate relative levels of expression of Th1- and Th2-
type cytokines.36 Both Th1 and Th2 responses are
involved in AD, and truly ‘polarized’ Th2 or Th1 cytokine
profiles are rarely identified. In one study, only 25% of
the atopic dog samples examined exhibited a clear ‘Th2’
cytokine profile, and only 25% of healthy skin samples
exhibited a clear ‘Th1’ profile.9 Another study investigat-
ing expression levels of multiple cytokines and transcrip-
tion factors also failed to identify a clearly polarized
profile.32
One study followed the cytokine profile of PBMCs from
spontaneously mite-sensitized dogs after culture with
mite allergens. Initially, transcription of both IL-4 and IFNc
was decreased relative to PBMCs from healthy control
dogs.36 Interleukin-4 transcription did not change follow-
ing allergen-specific immunotherapy, but IFNc transcrip-
tion increased, leading the authors to suggest that
evaluation of cytokine ratios may provide a more effective
estimate of immune response than absolute expression
values.36 Another study found a decreased ratio of IFNc
to IL-4 protein expression in dogs following experimental
sensitization to Dermatophagoides farinae extract.38
However, this decreased ratio became less apparent
upon repeated rechallenge, because IFNc protein expres-
sion increased over time.38
Regulatory cytokines
As mentioned elsewhere in this review, evaluation of the
role of regulatory mediators (such as IL-10, TGFb and
FOXP3) can be challenging, because some putative
immunosuppressive factors may also be pro-inflamma-
tory. Interleukin-10, in particular, can either mediate Th2-
type inflammation or downregulate immune responses.
Interpreting the role of these ‘regulatory mediators’ can
be complicated further when expression is increased in
inflamed skin. It is known that regulatory mechanisms
can be overwhelmed in certain circumstances, e.g. in the
presence of high levels of IL-6.50 For this reason, it is
often difficult to determine whether these multifunctional
cytokines are actively contributing to inflammation or are
attempting (and failing) to control it.
Transforming growth factor-b
Decreased TGFb expression has been reported in atopic
compared with healthy canine skin, although this has not
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been demonstrated consistently.30,32 In addition, expres-
sion of TGFb was found to be decreased after environ-
mental allergen challenge in experimentally sensitized
dogs.34
Interleukin-10
Elevated IL-10 expression has been demonstrated in
canine lesional atopic skin.32 In contrast, there was no
difference in spontaneous expression of IL-10 in circulat-
ing PBMCs from atopic and healthy dogs.45 Similar con-
flicting results have been seen in experimental models of
canine AD. In one study, cutaneous mRNA expression of
IL-10 did not change significantly following environmental
allergen challenge of mite-sensitized beagles.12 However,
a second study demonstrated decreased IL-10 expres-
sion in PBMCs after environmental allergen challenge in
sensitized beagles.34 As described above, the ability of
IL-10 to promote either Th2 or regulatory immune
responses may be at least a partial explanation for these
apparently contradictory results.
Forkhead box P3
To date, very little work has been performed to evaluate
the role of FOXP3 in the pathogenesis of canine atopic
dermatitis. In one study, a trend towards increased
FOXP3 expression was demonstrated in canine lesional
atopic skin, although this change was not statistically sig-
nificant.32 Allergen-specific immunotherapy has been
associated with an increase in circulating CD4+FOXP3+
Treg cells, whereas pre-immunotherapy Treg numbers
did not differ from those of healthy control dogs.51 The
presence of normal or even slightly supranormal FOXP3
expression suggests that clinical disease in canine AD
may be associated with a functionally decreased regula-
tory capability of cells expressing this transcript or pro-
tein.
Regulatory cytokines and immunotherapy
Allergen-specific immunotherapy may induce tolerance,
possibly through IL-10-associated mechanisms. In one
study, baseline serum IL-10 levels were similar in atopic
dogs and healthy dogs, but increased in atopic dogs fol-
lowing successful immunotherapy. Dogs with poor
responses to immunotherapy, in contrast, had signifi-
cantly lower IL-10 levels.51 However, in another study the
mRNA expression of IL-10 did not change significantly fol-
lowing immunotherapy with liposome–nucleic acid com-
plexes.37 In a third study, the number of circulating
CD4+FOXP3+ cells was found to increase following
immunotherapy.51 Taken together, these results suggest
that in some patients, allergen-specific immunotherapy
may be associated with an increase in regulatory T-cell
populations.
Other disease-related cytokines and chemokines
Numerous other cytokines can be present in atopic and
nonatopic inflammation. These include IL-1, IL-2, IL-6,
TNFa, IL-8 and IL-18.12,30,31 These cytokines are often
multifunctional and may mediate nonspecific or nonaller-
gic inflammation. It is therefore not entirely surprising
that expression values for these cytokines are often vari-
able or directly contradictory (Table 1).
Several studies have evaluated the role of chemotactic
cytokines in canine AD. Lesional atopic skin had
decreased mRNA expression of the cutaneous T-cell-
homing chemokine CCL27 compared with nonlesional
skin, whereas expression of CCL28 (which is chemotactic
for resting CD4+ and CD8+ cells as well as eosinophils)
was increased.42,52 Both lesional and nonlesional atopic
skin constitutively expressed CCL4, CCL19, CCL20,
CCL21 and CCL24 (eosinophil chemotactic protein 2).52
These factors are chemotactic for lymphocytes and
eosinophils and, to a lesser extent, neutrophils and mono-
nuclear cells. Unfortunately, no data from nonatopic
canine skin were provided for comparison. A gene
expression microarray analysis also demonstrated
increased expression of CCL19 (macrophage inhibitory
protein 3b; which is chemotactic for dendritic cells and
lymphocytes) in atopic relative to healthy skin.42
Noncytokine proteins in atopic dermatitis
Several noncytokine proteins have also been associated
with AD, including the calcium-binding protein S100A8.
This is a pro-inflammatory protein that has been shown to
induce chemotaxis in canine neutrophils. Release is stim-
ulated by TNFa, the levels of which are correlated with
clinical severity.53 The S100 gene is also located on the
epidermal differentiation complex with profilaggrin, lori-
crin and involucrin, which are essential for keratinocyte
and epidermal barrier differentiation.54 Serum levels of
S100A8 correlate with Canine Atopic Dermatitis Extent
and Severity Index scores in atopic dogs, and increased
gene expression was demonstrated in lesional atopic
skin.42,55–57 Finally, although a canine genome-wide link-
age study failed to detect any chromosomal regions sig-
nificantly linked to AD, the authors were unable to
exclude linkage to a 56 cM region on CFA (canine chro-
mosome) 7, which contains the gene for S100A8.58
Differential expression of serine peptidase inhibitor
clade B, member 4/squamous cell carcinoma antigen 2
(SERPINB4/SCCA2), serum amyloid A (SAA) and/or its
variant SAA3, tissue inhibitor of metalloproteinases 1
(TIMP1) and serine peptidase inhibitor, Kazal type 5
(SPINK5) have also been demonstrated in canine lesional
atopic skin, although these changes were not always sta-
tistically significant relative to nonlesional or control
skin.42,56,57 Many of these factors may be expressed non-
specifically in other inflammatory conditions. SERPINB4
appears to play a role in tumour metastasis.59,60 Serum
amyloid A belongs to a group of apolipoproteins that are
highly expressed in response to inflammation and tissue
injury and are considered part of the acute-phase
response.61 TIMPs are inhibitors of matrix metalloprotein-
ases, which are involved in the degradation of extracellu-
lar matrix proteins and may play a role in fibrosis and
tissue remodelling of chronic lesions.62,63 Finally, SPINK5
is a serine protease inhibitor that is involved in skin and
hair morphogenesis. Mutations of SPINK5 in humans
have been associated with Netherton syndrome, which is
characterized by ichthyosis and AD.64 Although none of
these factors is specific for allergic disease, it is interest-
ing to note that three of these are proteinase inhibitors. It
remains to be seen whether their upregulation is in
response to release of endogenous or exogenous proteo-
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lytic factors (in which case they might be expected to be
attempting to downregulate cutaneous inflammation) or if
they are actively participating in the inflammatory
response in some other fashion.
Microarrays/gene expression
Advances in gene expression microarray analysis technol-
ogy have permitted the simultaneous analysis of anything
from dozens to thousands of mRNA transcripts from rela-
tively small sample sizes. Expression microarrays may
evaluate the entire genome or they may be custom
designed to focus on more limited gene sets. Two stud-
ies used gene expression microarrays to evaluate pat-
terns of gene expression in canine AD.42,56 Although a
detailed discussion of the results of these studies is
beyond the scope of this manuscript, a summary of their
findings is presented here.
The first study evaluated gene expression in canine le-
sional atopic, nonlesional atopic and healthy skin.56 RNA
from these samples was hybridized to a canine-specific
Agilent 22K oligonucleotide array (Agilent Technologies,
Palo Alto, CA, USA), which evaluated the transcription of
~22,000 genes. Of the 22,000 genes, 54 were signifi-
cantly differentially expressed in atopic skin relative to
healthy skin. Sixteen of the 54 were differentially
expressed in atopic skin relative to healthy skin, 12 were
differentially expressed only in lesional skin and 26 were
differentially expressed only in nonlesional skin.
Genes that were differentially transcribed in both
lesional and nonlesional skin of atopic dogs could be
grouped by the following general functions: inflammation/
immunology; cell cycle/apoptosis/repair/lesion formation;
translational control; transport/regulation; barrier forma-
tion; and miscellaneous genes. Most of these genes
were upregulated relative to healthy skin and included
members of the GOLGA4 subfamily, which are involved
in ceramide transport to the cell surface.56
Genes differentially transcribed only in lesional atopic
skin included those involved in the following functions:
inflammation/immunology; cell cycle/apoptosis/repair/
lesion formation; transport/regulation; barrier formation;
and miscellaneous. With a single exception (cell death-
inducing DNA fragmentation factor A-like effector c;
CIDE-3 or CIDEC), all of these genes were upregulated
relative to healthy skin. These included S100A8, SAA and
SAA3, SERPINB4/SCCA2 and TIMP1.56
Genes differentially transcribed only in nonlesional skin
of atopic dogs had the following functions: inflammation/
immunology; cell cycle/apoptosis/repair/lesion formation;
transport/regulation; barrier formation; transcription fac-
tors; and miscellaneous. With few exceptions, these
genes were downregulated relative to their expression in
healthy skin.56
A second whole-genome microarray study also evalu-
ated lesional atopic, nonlesional atopic and healthy skin42
using the Affymetrix canine 2.0 genome. This array evalu-
ated the transcription of ~18,000 mRNA/expressed
sequence tag (EST) transcripts and a further 20,000 pre-
dicted genes. In this study, 1070 transcripts were differ-
entially expressed in acute lesional atopic skin compared
with healthy skin, 312 transcripts were differentially
expressed in nonlesional skin compared with healthy skin
and 764 transcripts were differentially transcribed in
acute lesional skin relative to nonlesional skin. The tran-
scription data sets from the atopic dogs shared common
network pathways with human AD and asthmatic chronic
rhinosinusitis with nasal polyps (aCRSwNP).
Genes that were differentially expressed in acute le-
sional skin had the following functions: genes corre-
sponding to alternatively activated (IL-4- or IL-13-induced)
monocytes; anti-apoptotic genes; cell adhesion; other
chemokines, interleukins and receptors; collagens; com-
plement-associated genes; eosinophil-associated G-pro-
tein-coupled receptors; other G-protein-coupled receptors
and associated signalling molecules; members of the IL-1
family, innate immunity receptors and Nod-like receptors;
interferon-induced genes; keratins; leucocyte immuno-
globulin-like receptors; lipid-associated genes; genes
involved in L-tryptophan metabolism; lymphocyte anti-
gens; mast cell-associated genes; proteases and prote-
ase inhibitors; S100 family proteins; solute carriers; and
transcription factors and zinc finger proteins.42
Some differences between these two studies are to be
expected given that different microarrays (each with its
own proprietary set of gene sequences in addition to
more commonly evaluated consensus genes), different
case populations and somewhat different analysis algo-
rithms were used. Despite this, the overall concordance
between the two array studies is striking. Both were able
to identify individual genes of interest as well as group-
ings of relevant genes. As such, these results may be
‘springboards’ towards more focused evaluation of novel
gene targets.
Conclusion
In summary, recent work has challenged the notion of AD
as a purely ‘Th2-polarized’ phenomenon. Markedly differ-
ent gene expression profiles for Th1, Th2, regulatory and
‘nonspecific’ cytokines are detected during different
phases of the disease. The development of more
advanced methods of gene and protein detection has
identified ‘new’ relevant inflammatory mediators and non-
cytokine factors. Furthermore, the advent of gene expres-
sion microarray technology provides the potential to
define inflammatory network pathways in canine AD fur-
ther and identify new targets for further study.
Acknowledgements
This paper was reviewed by members of the Interna-
tional Committee on Allergic Diseases in Animals (Di-
dier Carlotti, Richard Halliwell, Bruce Hammerberg,
Peter Hill, Alexander Koutinas, Kenichi Masuda, Thierry
Olivry, Jon Plant, Helen Power, Pascal Prelaud, Mano-
lis Saridomichelakis and Regina Wagner). The authors
gratefully acknowledge their contributions to this
work.
References
1. Hill PB, Olivry T. The ACVD task force on canine atopic dermati-
tis (V): biology and role of inflammatory cells in cutaneous aller-
gic reactions. Vet Immunol Immunopathol 2001; 81: 187–198.
© 2015 ESVD and ACVD, Veterinary Dermatology, 26, 124–e32.130
Pucheu-Haston et al.
2. Marsella R, Olivry T. The ACVD task force on canine atopic der-
matitis (VII): mediators of cutaneous inflammation. Vet Immunol
Immunopathol 2001; 81: 205–213.
3. Thepen T, Langeveld-Wildschut EG, Bihari IC et al. Biphasic
response against aeroallergen in atopic dermatitis showing a
switch from an initial TH2 response to a TH1 response in situ: an
immunocytochemical study. J Allergy Clin Immunol 1996; 97:
828–837.
4. Werfel T, Morita A, Grewe M et al. Allergen specificity of skin-
infiltrating T cells is not restricted to a type-2 cytokine pattern in
chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996;
107: 871–876.
5. Reinhold U, Kukel S, Goeden B et al. Functional characterization
of skin-infiltrating lymphocytes in atopic dermatitis. Clin Exp
Immunol 1991; 86: 444–448.
6. van der Heijden FL, Wierenga EA, Bos JD et al. High fre-
quency of IL-4-producing CD4+ allergen-specific T lympho-
cytes in atopic dermatitis lesional skin. J Invest Dermatol
1991; 97: 389–394.
7. Olivry T, Naydan DK, Moore PF. Characterization of the cutane-
ous inflammatory infiltrate in canine atopic dermatitis. Am J Der-
matopathol 1997; 19: 477–486.
8. Sinke JD, Thepen T, Bihari IC et al. Immunophenotyping of skin-
infiltrating T-cell subsets in dogs with atopic dermatitis. Vet
Immunol Immunopathol 1997; 57: 13–23.
9. Olivry T, Dean GA, Tompkins MB et al. Toward a canine model
of atopic dermatitis: amplification of cytokine-gene transcripts in
the skin of atopic dogs. Exp Dermatol 1999; 8: 204–211.
10. Nimmo Wilkie JS, Wilkie BN, Yager JA et al. Altered spontane-
ous and histamine-induced in vitro suppressor-cell function in
dogs with atopic dermatitis. Vet Immunol Immunopathol 1992;
30: 129–145.
11. Nimmo Wilkie JS, Yager JA, Wilkie BN et al. Abnormal cutane-
ous response to mitogens and a contact allergen in dogs with
atopic dermatitis. Vet Immunol Immunopathol 1991; 28: 97–
106.
12. Marsella R, Olivry T, Maeda S. Cellular and cytokine kinetics
after epicutaneous allergen challenge (atopy patch testing) with
house dust mites in high-IgE beagles. Vet Dermatol 2006; 17:
111–120.
13. Olivry T, Deangelo KB, Dunston SM et al. Patch testing of exper-
imentally sensitized beagle dogs: development of a model
for skin lesions of atopic dermatitis. Vet Dermatol 2006; 17:
95–102.
14. Marsella R, Olivry T, Nicklin C et al. Pilot investigation of a model
for canine atopic dermatitis: environmental house dust mite chal-
lenge of high-IgE-producing beagles, mite hypersensitive dogs
with atopic dermatitis and normal dogs. Vet Dermatol 2006; 17:
24–35.
15. Pucheu-Haston CM, Jackson HA, Olivry T et al. Epicutaneous
sensitization with Dermatophagoides farinae induces general-
ized allergic dermatitis and elevated mite-specific immunoglobu-
lin E levels in a canine model of atopic dermatitis. Clin Exp
Allergy 2008; 38: 667–679.
16. Olivry T, Dunston SM, Murphy KM et al. Characterization of the
inflammatory infiltrate during IgE-mediated late phase reactions
in the skin of normal and atopic dogs. Vet Dermatol 2001; 12:
49–58.
17. Maeda S, Tsukui T, Saze K et al. Production of a monoclonal anti-
body to canine thymus and activation-regulated chemokine
(TARC) and detection of TARC in lesional skin from dogs with
atopic dermatitis. Vet Immunol Immunopathol 2005; 103: 83–
92.
18. Maeda S, Ohmori K, Yasuda N et al. Increase of CC chemokine
receptor 4-positive cells in the peripheral CD4 cells in dogs with
atopic dermatitis or experimentally sensitized to Japanese cedar
pollen. Clin Exp Allergy 2004; 34: 1467–1473.
19. Simpson A, Maeda S, Marsella R. Temporal dynamic changes of
phenotypic expression of peripheral CD4 cells during environ-
mental allergen challenge in an experimental model of canine
atopic dermatitis: a pilot study. J Vet Med Sci 2009; 71: 1177–
1181.
20. Maeda S, Okayama T, Omori K et al. Expression of CC chemoki-
ne receptor 4 (CCR4) mRNA in canine atopic skin lesion. Vet
Immunol Immunopathol 2002; 90: 145–154.
21. Tarpataki N, Terenyi M, Nagy SZ. Changes in the CD4/CD8-posi-
tive T lymphocyte ratio in the blood of atopic and non-atopic
dogs. Vet Dermatol 2012; 23 (Suppl 1): 58 (abstract).
22. Olivry T, Wofford J, Paps JS et al. Stratum corneum removal
facilitates experimental sensitization to mite allergens in atopic
dogs. Vet Dermatol 2011; 22: 188–196.
23. Masuda K, Yasuda N. The antibody against human CD25, ACT-1,
recognizes canine T-lymphocytes in the G2/M and G0/G1 phases
of the cell cycle during proliferation. J Vet Med Sci 2008; 70:
1285–1287.
24. Mizuno T, Suzuki R, Umeki S et al. Crossreactivity of antibodies
to canine CD25 and Foxp3 and identification of canine
CD4+CD25+Foxp3+ cells in canine peripheral blood. J Vet Med
Sci 2009; 71: 1561–1568.
25. Abbas AK, Lichtman AH, Pillai S (eds). Immunologic tolerance
and autoimmunity. In: Cellular and Molecular Immunology. Phila-
delphia, PA: Elsevier Saunders, 2012; 326.
26. Abbas AK, Lichtman AH, Pillai S (eds). Activation of T lympho-
cytes. In: Cellular and Molecular Immunology. 7th edition. Phila-
delphia, PA: Elsevier Saunders, 2012; 210.
27. Garden OA, Pinheiro D, Cunningham F. All creatures great and
small: regulatory T cells in mice, humans, dogs and other
domestic animal species. Int Immunopharmacol 2011; 11: 576–
588.
28. Lin T-Y, London CA. A functional comparison of canine and mur-
ine bone marrow derived cultured mast cells. Vet Immunol Im-
munopathol 2006; 114: 320–334.
29. Archer TM, Fellman CL, Stokes JV et al. Pharmacodynamic
monitoring of canine T-cell cytokine responses to oral cyclospor-
ine. J Vet Intern Med 2011; 25: 1391–1397.
30. Nuttall TJ, Knight PA, McAleese SM et al. Expression of
Th1, Th2 and immunosuppressive cytokine gene transcripts
in canine atopic dermatitis. Clin Exp Allergy 2002; 32: 789–
795.
31. Maeda S, Fujiwara S, Omori K et al. Lesional expression of thy-
mus and activation-regulated chemokine in canine atopic derma-
titis. Vet Immunol Immunopathol 2002; 88: 79–87.
32. Schlotter YM, Rutten VP, Riemers FM et al. Lesional skin in ato-
pic dogs shows a mixed Type-1 and Type-2 immune responsive-
ness. Vet Immunol Immunopathol 2011; 143: 20–26.
33. Pucheu-Haston CM, Shuster D, Olivry T et al. A canine
model of cutaneous late-phase reactions: prednisolone inhibi-
tion of cellular and cytokine responses. Immunology 2006;
117: 177–187.
34. Maeda S, Tsuchida H, Marsella R. Allergen challenge decreases
mRNA expression of regulatory cytokines in whole blood of
high-IgE beagles. Vet Dermatol 2007; 18: 422–426.
35. Fujiwara S, Yasunaga S, Iwabuchi S et al. Cytokine profiles of
peripheral blood mononuclear cells from dogs experimentally
sensitized to Japanese cedar pollen. Vet Immunol Immunopa-
thol 2003; 93: 9–20.
36. Shida M, Kadoya M, Park SJ et al. Allergen-specific immunother-
apy induces Th1 shift in dogs with atopic dermatitis. Vet Immu-
nol Immunopathol 2004; 102: 19–31.
37. Mueller RS, Veir J, Fieseler KV et al. Use of immunostimulatory
liposome-nucleic acid complexes in allergen-specific immuno-
therapy of dogs with refractory atopic dermatitis – a pilot study.
Vet Dermatol 2005; 16: 61–68.
38. McCandless EE, Rugg CA, Fici GJ et al. Allergen-induced pro-
duction of IL-31 by canine Th2 cells and identification of immune,
skin, and neuronal target cells. Vet Immunol Immunopathol
2014; 157: 42–48.
39. Klukowska-R€otzler J, Chervet L, M€uller EJ et al. Expression of
thymic stromal lymphopoietin in canine atopic dermatitis. Vet
Dermatol 2013; 24: 54–59.
© 2015 ESVD and ACVD, Veterinary Dermatology, 26, 124–e32. 131
Lymphocytes, cytokines and chemokines in AD
40. Mizuno T, Kanbayashi S, Okawa T et al. Molecular cloning of
canine interleukin-31 and its expression in various tissues. Vet
Immunol Immunopathol 2009; 131: 140–143.
41. Gonzales AJ, Humphrey WR, Messamore JE et al. Interleukin-
31: its role in canine pruritus and naturally occurring canine ato-
pic dermatitis. Vet Dermatol 2013; 24: 48–53, e11–e12.
42. Plager DA, Torres SM, Koch SN et al. Gene transcription abnor-
malities in canine atopic dermatitis and related human eosino-
philic allergic diseases. Vet Immunol Immunopathol 2012; 149:
136–142.
43. Romagnani S. Regulation of the T cell response. Clin Exp Allergy
2006; 36: 1357–1366.
44. Schroder K, Hertzog PJ, Ravasi T et al. Interferon-c: an overview
of signals, mechanisms and functions. J Leukoc Biol 2004; 75:
163–189.
45. Hayashiya S, Tani K, Morimoto M et al. Expression of T helper 1
and T helper 2 cytokine mRNAs in freshly isolated peripheral
blood mononuclear cells from dogs with atopic dermatitis. J Vet
Med A Physiol Pathol Clin Med 2002; 49: 27–31.
46. Vignali DAA, Kuchroo VK. IL-12 family cytokines: immunological
playmakers. Nat Immunol 2012; 13: 722–728.
47. Abdi K. IL-12: the role of p40 versus p75. Scand J Immunol
2002; 56: 1–11.
48. Ma X, D’Andrea A, Kubin M et al. Production of interleukin-12.
Res Immunol 1995; 146: 432–438.
49. D’Andrea A, Rengaraju M, Valiante NM et al. Production of natu-
ral killer cell stimulatory factor (interleukin 12) by peripheral
blood mononuclear cells. J Exp Med 1992; 176: 1387–1398.
50. Goodman WA, Young AB, McCormick TS et al. Stat3 phosphor-
ylation mediates resistance of primary human T cells to regula-
tory T cell suppression. J Immunol 2011; 186: 3336–3345.
51. Keppel KE, Campbell KL, Zuckermann FA et al. Quantitation of
canine regulatory T cell populations, serum interleukin-10 and
allergen-specific IgE concentrations in healthy control dogs and
canine atopic dermatitis patients receiving allergen-specific
immunotherapy. Vet Immunol Immunopathol 2008; 123: 337–
344.
52. Maeda S, Tsuchida H, Shibata S et al. Expression analysis of
CCL27 and CCL28 mRNA in lesional and non-lesional skin of
dogs with atopic dermatitis. J Vet Med Sci 2008; 70: 51–55.
53. Nuttall T, Knight PA, McAleese SM et al. Expression of
T-helper 1 cytokine mRNA in canine atopic dermatitis correlates
with clinical severity. In: Hillier A, Foster AP, Kwochka KW, eds.
Advances in Veterinary Dermatology, volume 5. Oxford, UK:
Blackwell Publishing, 2004; 17–27.
54. Candi E, Schmidt R, Melino G. The cornified envelope: a model
of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6: 328–340.
55. Chung TH, Oh JS, Lee YS et al. Elevated serum levels of S100
calcium binding protein A8 (S100A8) reflect disease severity in
canine atopic dermatitis. J Vet Med Sci 2010; 72: 693–700.
56. Merryman-Simpson AE, Wood SH, Fretwell N et al. Gene
(mRNA) expression in canine atopic dermatitis: microarray analy-
sis. Vet Dermatol 2008; 19: 59–66.
57. Wood SH, Clements DN, Ollier WE et al. Gene expression in
canine atopic dermatitis and correlation with clinical severity
scores. J Dermatol Sci 2009; 55: 27–33.
58. Salzmann CA, Olivry TJ, Nielsen DM et al. Genome-wide linkage
study of atopic dermatitis in West Highland White Terriers. BMC
Genet 2011; 12: 37–42.
59. Murakami A, Nakagawa T, Kaneko M et al. Suppression of SCC
antigen promotes cancer cell invasion and migration through the
decrease in E-cadherin expression. Int J Oncol 2006; 29: 1231–
1235.
60. Murakami A, Fukushima C, Yositomi K et al. Tumor-related pro-
tein, the squamous cell carcinoma antigen binds to the intracellu-
lar protein carbonyl reductase. Int J Oncol 2010; 36: 1395–1400.
61. Eklund KK, Niemi K, Kovanen P. Immune functions of serum
amyloid A. Crit Rev Immunol 2012; 32: 335–348.
62. Harper JI, Godwin H, Green A et al. A study of matrix metallo-
proteinase expression and activity in atopic dermatitis using a
novel skin wash sampling assay for functional biomarker analy-
sis. Br J Dermatol 2010; 162: 397–403.
63. Katoh N, Hirano S, Suehiro M et al. Increased levels of serum
tissue inhibitor of metalloproteinase-1 but not metalloprotein-
ase-3 in atopic dermatitis. Clin Exp Immunol 2002; 127: 283–
288.
64. Nishio Y, Noguchi E, Shibasaki M et al. Association between
polymorphisms in the SPINK5 gene and atopic dermatitis in the
Japanese. Genes Immun 2003; 4: 515–517.
Resume
Contexte – Le developpement de la dermatite atopique (AD) et des autres hypersensibilites cutanees im-
plique la differenciation et l’activation des lymphocytes specifiques d’allergenes. Bien que l’hypersensibilite
soit souvent consideree comme etant une reponse lymphocytaire polarisee T-helper-2, une preuve recente
suggere que la maladie clinique est associee au developpement de phenotypes lymphocytaires multiples.
Objectifs – Le but de cet article est de revoir les donnees recentes dans la comprehension des ro^les des
lymphocytes, des cytokines et des facteurs non-cytokiniques dans la pathogenie de la dermatite atopique
canine.
Methodes – Les bases de donnees, les resumes et les proceedings des congres internationaux publies
entre 2001 et 2013 ont ete revus dans cette mise a jour. Lorsque necessaire, des articles plus anciens eta-
ient inclus pour plus d’information.
Resultats – Le developpement de l’AD canine est associe a des changements des populations lymphocy-
taires cutanees et circulantes. Ces reponses lymphocytaires sont caracterisees par la production d’une
variete complexe de cytokines n’incluant pas seulement les T-helper-2 mais aussi les T-helper-1, T-helper-
17 et les cellules T regulatrices. En outre, l’analyse de l’expression des genes par puces a permis d’identi-
fier un certain nombre de facteurs non-cytokiniques semblant e^tre associe avec l’inflammation atopique.
Ceci inclut la proteine S100A8, la serum amylo€ıde A et un certain nombre d’inhibiteurs de proteases ainsi
que des genes impliques dans la formation de la barriere epidermique, les recepteurs de l’immunite innee,
les proteines du cycle cellulaire et l’apoptose.
Conclusions – Le developpement de l’AD du chien est caracterise par le developpement d’une balance
delicate entre une variete de phenotypes cellulaires et de mediateurs de l’inflammation, comprenant des
cytokines, chemokines et des facteurs non-cytokiniques.
Resumen
Introduccion – el desarrollo de la dermatitis atopica (AD) y de otros procesos de hipersensibilidad cutanea
implica la activacion y diferenciacion de linfocitos especıficos de alergeno. Aunque la hipersensibilidad se
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considera a menudo polarizada a una respuesta de linfocitos ayudantes de tipo dos, hallazgos recientes
sugieren que la enfermedad clınica esta asociada con el desarrollo de fenotipos multiples de linfocitos.
Hipotesis/Objetivos – el objetivo de este artıculo fue revisar avances recientes en la comprension del pa-
pel de linfocitos, citoquina y factores no relacionados con citoquinas en la patogenia de la dermatitis atopica
canina.
Metodos – se revisaron para este artıculo citas en base de datos, resumenes y manuales de reuniones in-
ternacionales publicadas entre los a~nos 2001 a 2013. Cuando fue necesario, se incluyeron citas de artıculos
mas antiguos como informacion de soporte
Resultados – el desarrollo de la dermatitis atopica canina esta asociado con cambios en las poblaciones de
linfocitos cutaneos y circulantes. Esta respuesta linfocitaria esta caracterizadas por la produccion una varie-
dad compleja de citoquinas, incluyendo no solo citoquinas de tipo T2 ayudante, sino tambien de tipo T1, T
17 ayudante, y respuestas regulatorias de linfocitos T. Ademas, mediante analisis de la expresion genica
en micro matrices se han identificado un numero de factores no relacionadas con citoquinas que estan aso-
ciados con la inflamacion durante la atopia. Estos factores incluyen la proteına S100A8 de union al calcio,
amiloide serico de tipo A, y un numero de inhibidores de proteasas, ası como genes implicados en la form-
acion de la barrera de la piel, receptores de inmunidad innata, proteınas del ciclo celular y de apoptosis.
Conclusiones e importancia clınica – el desarrollo de la dermatitis atopica en perros se caracteriza por la
aparicion de un balance delicado entre una variedad de fenotipos de linfocitos T y de mediadores de inflam-
acion, incluyendo citoquinas, quimioquinas y factores no relacionados con citoquinas.
Zusammenfassung
Hintergrund – Zur Entwicklung der atopischen Dermatitis (AD) und anderer kutaner Hypersensibilit€aten
geh€ort die Aktivierung und Differenzierung der allergen-spezifischen Lymphozyten. Obwohl die Hypersen-
sibilit€at oft als „T-Helfer 2-polarisierte” Lymphozytenantwort verstanden wird, weist j€ungste Evidenz darauf
hin, dass die klinische Erkrankung mit der Entwicklung multipler Lymphozyten Ph€anotypen einhergeht.
Ziele – Das Ziel dieser Publikation ist es j€ungste Fortschritte beim Verst€andnis der Rollen der Lymphozyten,
der Zytokine und der nicht-Zytokinen Faktoren bei der Pathogenese der AD des Hundes zu reviewen.
Methoden – Die Zitationsdatenbanken, Abstracts und Proceedings von internationalen Treffen, die zwis-
chen 2001 und 2013 publiziert worden waren, wurden reviewed. Wo es n€otig war, wurden €altere Artikel
f€ur die Hintergrundinformation inkludiert.
Ergebnisse – Die Entstehung der caninen AD h€angt sowohl mit Ver€anderungen der kutanen wie auch der
zirkulierenden Lymphozytenpopulationen zusammen. Diese Lymphozytenpopulationen werden charakte-
risiert durch die Produktion einer komplexen Variation an Zytokinen, welche nicht nur aus T-Helfer 2, sond-
ern auch aus T-Helfer 1, T-Helfer 17 und regulatorischen T-Zell Reaktionen bestanden. Zus€atzlich hat es die
Mikroarray Genexprimierungsanalyse m€oglich gemacht, eine Anzahl an nicht-Zytokinen Faktoren zu identi-
fizieren, die bei der atopischen Entz€undung vorkommen. Zu diesen Faktoren z€ahlen das Kalzium-bindende
Protein S100A8, Serum Amyloid A und einige Protease Inhibitoren, sowie Gene, die bei der Bildung der epi-
dermalen Barriere beteiligt waren; angeborene Immunrezeptoren, Zellzyklusproteine und die Apoptose.
Schlussfolgerungen – Die Entstehung der AD der Hunde wird durch die Entwicklung einer delikaten Bal-
ance zwischen einer Vielzahl von T-Zell Ph€anotypen und Entz€undungsmediatoren, wie Zytokine, Chemoki-
ne und nicht-Zytokine Faktoren charakterisiert.
摘要
背景 – 异位性皮炎(AD)和其他皮肤过敏症的发生,与抗原特异性淋巴细胞的激活和分化有关。过敏症经常被
认为是“T辅助细胞2极化”的反应,但是最近有证据显示这种疾病是多重淋巴细胞表型出现的结果。
目的 – 本文目的是回顾近期淋巴细胞、细胞因子和非细胞因子,理解其对犬AD发病机制所起作用的最新进
展。
方法 – 引用发表于2001至2013年之间国际会议发表的数据、摘要和会议记录,基于这些更新进行综述。
结果 –犬AD的发病与皮肤和循环淋巴细胞群的变化有关。这些淋巴细胞的反应以产生复合多样的细胞因子
为特征,其中不仅包括T辅助细胞2,也有T辅助细胞1、17,以及调解T细胞反应。另外,微阵列基因表达分析能
够鉴别许多非细胞因子,这些细胞因子都显现与异位性炎症有关。它们包括钙连蛋白S100A8、血清淀粉样A
和一些蛋白酶抑制剂,以及表皮屏障形成、先天免疫受体、细胞循环蛋白和凋亡基因。
结论 – 犬的AD发生特征,是在多种T细胞表型和炎性介质,包括细胞因子、趋化因子和非细胞因子之间,发生
了微妙的平衡。
要約
背景 – アトピー性皮膚炎(AD)およびその他の皮膚過敏症の発生はアレルゲン特的リンパ球の活性化や分化に関与し
ている。過敏症はしばしば’Tヘルパー2極性’リンパ球反応と考えられているが、新しいエビデンスによると臨床疾患が複
数のリンパ球表現型の発達と関係していると示唆されている。
目的 – この論文の目的はイヌADの病因におけるリンパ球、サイトカイン、非サイトカイン因子の役割の理解についての最
近の進歩を総括することである。
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方法 – 文献引用データベース、2001年から2013年の間に発表された国際会議での要約や抄録をこの最新情報
で再検討した。必要な場合は、背景にある情報のための古い論文を含んでいる。
結果 – イヌADの発生には皮膚と循環するリンパ球の集団の両方の変化が関係している。それらのリンパ球反応は、
Tヘルパー2だけでなくTヘルパー1、Tヘルパー17ならびに制御性T細胞反応を含む、複雑で多様なサイトカイ
ンの産生により特徴付けられている。さらに、マイクロアレイ遺伝子発現解析によりアトピー性炎症と関連すると思われる
非サイトカイン因子の数を特定することが可能となった。それらにはカルシウム結合タンパクS100A8、血清アミロイド、な
らびにプロテアーゼ阻害剤の数だけでなく、表皮バリア形成、自然免疫受容体、細胞周期プロテインおよびアポトー
シスに関連した遺伝子が含まれている。
結論 – イヌにおけるADの発生は多様なT細胞表現型およびサイトカイン、ケモカインならびに非サイトカイン因子を含む
炎症性メディエーターの間の繊細なバランスの発達によって特徴付けられる。
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